Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,885 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,373)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06987708 | Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers | not yet recruiting | N/A | 67 | Hackensack Meridian HealthOTHER | 0 | Aug 24, 2026 | clinicaltrials |
| NCT07615270 | A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement | not yet recruiting | Early Phase 1 | 5 | Stanford UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07667868 | A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 18 | BrightPath Biotherapeutics Co., Ltd.INDUSTRY | 0 | Aug 21, 2026 | clinicaltrials |
| NCT07588698 | Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma | not yet recruiting | Phase 2 | 20 | Carrie Ho, MDOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07724457 | Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma | not yet recruiting | Phase 2 / Phase 3 | 271 | National Cancer Institute (NCI)NIH | 0 | Aug 19, 2026 | clinicaltrials |
| NCT07763210 | Lazarus: IT Therapy for ICANS | not yet recruiting | Phase 2 | 59 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07774234 | Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 39 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07774377 | Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma(CHI-HSCT) | not yet recruiting | Phase 3 | 132 | First Affiliated Hospital of Zhejiang UniversityOTHER | 0 | Aug 19, 2026 | clinicaltrials |
| NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Phase 1 / Phase 2 | 30 | BeOne MedicinesINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT07771361 | BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma | not yet recruiting | Phase 2 | 90 | Luminary TherapeuticsINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT07735533 | A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies | not yet recruiting | Phase 1 / Phase 2 | 274 | Umoja BiopharmaINDUSTRY | 0 | Aug 17, 2026 | clinicaltrials |
| NCT07735546 | A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 100 | Umoja BiopharmaINDUSTRY | 0 | Aug 17, 2026 | clinicaltrials |
| NCT07767799 | Biological Analysis of MABs in NHL in a Translational Prospective Observational Study Within Italian Clinical Practice(BIO-FIL_MAB) | not yet recruiting | — | 1,000 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07768943 | GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 620 | Fudan UniversityOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07662928 | Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study | not yet recruiting | Phase 2 | 43 | AIDS Malignancy ConsortiumNETWORK | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07764601 | R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma(RM-MA-PD1) | not yet recruiting | N/A | 58 | WEI XUOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07764861 | A Open-Label Phase in Participants With Multiple Myeloma | not yet recruiting | Phase 2 | 120 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07766421 | Evaluation of Iopofosine I 131 vs. R-CD in WM Patients | not yet recruiting | Phase 3 | 219 | Cellectar Biosciences, Inc.INDUSTRY | 0 | Aug 14, 2026 | clinicaltrials |
| NCT07649304 | AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") | not yet recruiting | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 0 | Aug 13, 2026 | clinicaltrials |
| NCT07759661 | Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies(IMPACT) | not yet recruiting | — | 64 | IRCCS San RaffaeleOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07759102 | Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma | not yet recruiting | Phase 1 | 20 | University of California, DavisOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07760610 | Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response | not yet recruiting | Phase 4 | 27 | The First Hospital of Jilin UniversityOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT07313852 | A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Phase 1 / Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07757412 | Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.(ADAPTATION) | not yet recruiting | Phase 2 | 50 | Odense University HospitalOTHER | 4 | Aug 11, 2026 | clinicaltrials |
| NCT07758673 | Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma | not yet recruiting | Phase 1 | 16 | City of Hope Medical CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07009899 | BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)(RECLAIM) | not yet recruiting | Phase 2 | 34 | Medical College of WisconsinOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07221032 | FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 12 | Medical College of WisconsinOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07754682 | Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma(PREV-CART) | not yet recruiting | Phase 3 | 228 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Aug 10, 2026 | clinicaltrials |
| NCT07751471 | BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)(AL-004) | not yet recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07518329 | Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.(SAPPHIRE) | not yet recruiting | Phase 1 | 46 | Arovella Therapeutics LtdINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07736950 | A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma(RAZOR) | not yet recruiting | Phase 3 | 138 | Australasian Leukaemia and Lymphoma GroupOTHER | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07744750 | Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma | not yet recruiting | Phase 2 | 40 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07748689 | Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.(REBEL) | not yet recruiting | Phase 2 | 228 | Polish Myeloma ConsortiumOTHER | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07749976 | GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 108 | VitruviaeINDUSTRY | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07526597 | Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors(STOP-CLL-DCT) | not yet recruiting | Phase 2 | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07712588 | Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) | not yet recruiting | Phase 2 / Phase 3 | 880 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07746245 | The Efficacy of CAPCT in Patients With PTCL | not yet recruiting | Phase 2 | 58 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07742527 | A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care(DynaMMic-2) | not yet recruiting | Phase 1 | 22 | GlaxoSmithKlineINDUSTRY | 0 | Aug 3, 2026 | clinicaltrials |
| NCT07738887 | Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations(EVITA) | not yet recruiting | Phase 2 | 44 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jul 31, 2026 | clinicaltrials |
| NCT07740486 | A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease(TiTan) | not yet recruiting | Phase 3 | 248 | Polish Myeloma ConsortiumOTHER | 0 | Jul 31, 2026 | clinicaltrials |
| NCT07072585 | Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) | not yet recruiting | Phase 2 / Phase 3 | 1,708 | Children's Oncology GroupNETWORK | 0 | Jul 30, 2026 | clinicaltrials |
| NCT07735637 | A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).(DURGA-6) | not yet recruiting | Phase 3 | 750 | AstraZenecaINDUSTRY | 15 | Jul 30, 2026 | clinicaltrials |
| NCT07459608 | Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma | not yet recruiting | Phase 2 | 75 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07732712 | Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells | not yet recruiting | Phase 2 / Phase 3 | 15 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 0 | Jul 29, 2026 | clinicaltrials |
| NCT07727668 | Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) | not yet recruiting | Early Phase 1 | 22 | Shambavi RichardOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07728188 | A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma | not yet recruiting | Phase 3 | 520 | AbbVieINDUSTRY | 13 | Jul 27, 2026 | clinicaltrials |
| NCT07729397 | Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)(ANCILE-30) | not yet recruiting | Phase 1 | 21 | The Methodist Hospital Research InstituteOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07724782 | Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCL | not yet recruiting | Phase 1 / Phase 2 | 33 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07725406 | Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma(Prime REMIX) | not yet recruiting | Phase 1 | 32 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07725705 | SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL) | not yet recruiting | Phase 1 / Phase 2 | 44 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 24, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 24, 2026source: clinicaltrials